-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fable lymphoma (FL) is a heterogeneic disease and is the second most common subtype of non-Hodgkin's lymphoma (NHL) in the United States, accounting for about 20% of all NHL morbidity.
FL is defined as the proliferation of B cells at the center of malignant birth.
that although the treatments currently available have significantly improved the overall survival rate of FL patients, the disease remains incurable.
most or experience disease progress after initial treatment, after which they experience multiple relapses and require follow-up treatment.
Although there are a number of treatment options for primary and relapse/refractive FL (r/r FL), there are still unsatisfying medical needs in the FL, especially in patients with high risk of recurrence, histological changes, or insatiability with existing therapies.
Pharmaceuticals ( FDA ) has awarded its new Bcl-2 inhibitor APG-2575 orphan drug ( ODD ) for the treatment of fable lymphoma ( FL ) , the clinical stage biotechnology company announced today .
previously, APG-2575 had received ODD for the treatment of Waldenström globulinemia (WM), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).
year, the U.S. Food and Drug Administration (FDA) has awarded 10 ODDs to four drug candidates for Ascentage Pharma, the highest number of biopharmaceutical companies in China.
